rss
Br J Ophthalmol 1999;83:1153-1158 doi:10.1136/bjo.83.10.1153
  • Original Article
    • Clinical science

Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis

  1. Jayakrishna Ambati★,a,
  2. Kevin B Wynnea,
  3. Mary C Angerameb,
  4. Michael R Robinson†,a
  1. aDepartment of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, bDepartment of Nursing, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA★Current address: Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
  2. †Current address: National Eye Institute/National Institutes of Health, Bethesda, MD 20892, USA.
  1. Michael R Robinson, MD, 10 Center Drive, National Eye Institute/National Institutes of Health, Building 10, Room 10N112, Bethesda, MD 20892, USA.
  • Accepted 28 May 1999

Abstract

AIM Intravenous cidofovir is used to treat cytomegalovirus (CMV) retinitis, and has been reported to cause anterior uveitis. Relations were sought between this complication and patient characteristics that might help predict its occurrence.

METHODS 17 patients with AIDS and CMV retinitis who were treated with intravenous cidofovir were identified, and the following data collected in a retrospective chart review: demographic characteristics, duration of CMV retinitis, retinal lesion characteristics, dose and duration of cidofovir therapy, tests of renal function, CD4+ T lymphocyte counts, visual acuity, intraocular pressure, iris colour, history of diabetes mellitus, and use of concomitant medications. Case-control analyses were performed to determine risk factors for developing cidofovir associated uveitis.

RESULTS Anterior uveitis characterised by pain, ciliary injection, and decreased visual acuity occurred in 10 patients (59%). Median interval to development of uveitis was 11 doses of cidofovir. Symptoms developed 4.4 (SD 2.5) days (median 3.5) after an infusion of cidofovir. Patients who developed uveitis had a significantly greater rise in CD4+ T lymphocyte count while receiving cidofovir (68.4 (75.7) ×106/l versus 5.0 (0.6) ×106/l, (p = 0.04)). By stepwise linear regression, this factor accounted for 33% (p = 0.03) of the effect of developing uveitis. Mean follow up time, intraocular pressure decline during cidofovir therapy, serum creatinine and urine protein concentrations, and rates of protease inhibitor use were not significantly different between patients who developed uveitis and those who did not. Uveitis responded to topical corticosteroids and cycloplegia.

CONCLUSION Anterior uveitis in patients receiving intravenous cidofovir therapy may be related to improving immune function. The uveitis responds to treatment and may not preclude continuation of cidofovir.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.